Canadian company develops nose-to-brain technology for fast-acting cannabinoid treatments.

Written By Eloïse Cowan


According to Proactive Investors, the Canadian company PreveCeutical Medical has developed a sustained-release CBD formulation of their Sol-gel pain-relief technology. These easy-to-use treatments release cannabinoids into the central nervous system through nasal mucosal tissue.

While the Sol-gel drug delivery and research program is still in the final stages of testing, PreveCeutical has already begun a new search for new therapeutic products such as non-addictive analgesic peptides to treat athletes who are suffering from concussions.

Eloïse Cowan
Previous

A history of research into light therapy as a potential treatment for persistent concussion symptoms and possible CTE
Next

Day-long course on managing vision deficits after mild or moderate TBI